About Xencor (NASDAQ:XNCR)

Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.

Receive XNCR News and Ratings via Email

Sign-up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter.

Profitability

Miscellaneous

Xencor (NASDAQ:XNCR) Frequently Asked Questions

What is Xencor's stock symbol?

Xencor trades on the NASDAQ under the ticker symbol "XNCR."

How were Xencor's earnings last quarter?

Xencor Inc (NASDAQ:XNCR) posted its quarterly earnings results on Tuesday, August, 2nd. The biopharmaceutical company reported $1.13 EPS for the quarter, beating the Zacks' consensus estimate of ($0.18) by $1.31. The biopharmaceutical company had revenue of $66 million for the quarter, compared to analysts' expectations of $7.43 million. Xencor had a negative net margin of 148.29% and a negative return on equity of 15.26%. View Xencor's Earnings History.

Where is Xencor's stock going? Where will Xencor's stock price be in 2018?

6 analysts have issued 12 month price targets for Xencor's stock. Their forecasts range from $21.00 to $36.00. On average, they anticipate Xencor's stock price to reach $30.80 in the next year. View Analyst Ratings for Xencor.

What are Wall Street analysts saying about Xencor stock?

Here are some recent quotes from research analysts about Xencor stock:

1. According to Zacks Investment Research, "Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. " (2/20/2018)

2. Instinet analysts commented, "We are initiating on XNCR with a Neutral rating and a $21 target price. We recommend stepping to the sidelines in 2017, as we anticipate that XNCR shares will trade flat relative to the biotechnology index over the next 12 months. We note that several near-term catalysts are likely already 'baked in' the current valuation, particularly for the '5871 IgG4- RD program. We believe that a key catalyst'meaningful data for XNCR's bispecific assets'is likely to lead to upside, but that it will occur beyond our 12-month horizon." (3/1/2017)

Who sold Xencor stock? Who is selling Xencor stock?

Xencor's stock was sold by a variety of institutional investors in the last quarter, including Teachers Advisors LLC, BlackRock Inc., TIAA CREF Investment Management LLC, Wells Fargo & Company MN, Bank of New York Mellon Corp, Falcon Point Capital LLC, Metropolitan Life Insurance Co. NY and Rhumbline Advisers. Company insiders that have sold Xencor company stock in the last year include Bruce L A Carter, Edgardo Baracchini Jr, John J Kuch and Paul A Foster. View Insider Buying and Selling for Xencor.

How do I buy Xencor stock?

Shares of Xencor can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Xencor's stock price today?

One share of Xencor stock can currently be purchased for approximately $25.13.

How big of a company is Xencor?

Xencor has a market capitalization of $1.19 billion and generates $87.52 million in revenue each year. The biopharmaceutical company earns $23.62 million in net income (profit) each year or ($1.00) on an earnings per share basis. Xencor employs 83 workers across the globe.

How can I contact Xencor?

Xencor's mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company can be reached via phone at 626-305-5900 or via email at [email protected]

MarketBeat Community Rating for Xencor (XNCR)

MarketBeat's community ratings are surveys of what our community members think about Xencor and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Xencor (NASDAQ:XNCR) Analysts' Consensus Rating

MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.

MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.